Treatment with stereotactic ablative body radiotherapy resulted in no observed local failures or cancer-related deaths among patients with primary renal cell cancer.
The conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.
BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Recent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Improvement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Cybersecurity training is vital because it is mandated by HIPAA.
Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.
The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.
In this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.
NGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
Expert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.
Program encompasses patient counseling, anesthetic planning, and early mobilization.
Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
An approach combining chemotherapy and immunotherapy could help preserve quality of life.
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Drs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
Adjuvant pembrolizumab reduced the risk of disease recurrence or death, but did not improve overall survival, compared with observation in patients with urothelial carcinoma.
A urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.
Health care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.